MG Matt Gline Biotech industry voice who hosts Off-Target Effects with Matt Gline, a BiotechTV interview series with investors and company leaders such as Perceptive's Joe Ed...

“What you want from FDA is they tell you one thing, and then you spend a bunch of money and run a trial and take all this risk. Then you get the data, go back to FDA and say, we did the thing we said we were going to do. You want the FDA that you come back to to have a consistent view with the one they had years before. Stability matters. Uncertainty is harmful.”

Biotech Hangout · Health & Longevity · November 2026

“What you want from FDA is they tell you one thing, and then you spend a bunch of money and run a trial and take all this risk. Then you get the data, go back to FDA and say, we did the thing we said we were going to do. You want the FDA that you come back to to have a consistent view with the one they had years before. Stability matters. Uncertainty is harmful.” — Matt Gline, Biotech Hangout

Context

Reacting to the withdrawal of a nominee for FDA commissioner, Gline, who runs a drug company, explains what developers actually need from the agency. His point is that consistency across the years a trial takes matters more than any one policy.

Transcript

Biotech Hangout Around 15:33 into the episode
Brian Skorney

…and the Trump administration. And I don't know if anyone else has any perspectives from the industry side of things, but are we worried about sort of consistency and some sort of standardization of the FDA here? Does this make it even more uncertain how drug decisions are going to be made? Yeah,

Graig Suvannavejh

…So I do think it's going to result in a stalemate. I think it's going to, Brian, to your point, I think we're going to have a lot of uncertainty. And I hope Kyle, the fact that he's there might be the best thing we have for a protracted, lengthy confirmation process for a new FDA commissioner.

Matt Gline

My only comment on this is: as a company, what you want from FDA, the single most important thing you can get from FDA is they tell you one thing, and then you go off and you spend a bunch of money and you run a trial and you like, you hope that it works and you take all this risk. And then like you get the data and then you go back to FDA and you're like, okay, we did the thing we said we were going to do. Now, like, what next? Is you want the FDA that you come back to to have the same view, or at least a consistent view with the one they had years before. And so stability matters. Uncertainty is harmful. I'll say, like, over the last 24 months through everything that has happened politically, it's like the FDA has held it together pretty well. Like, there have been some glaring public complicated exceptions, but like mostly drugs are getting approved. Our interactions with FDA have been professional. They've been thoughtful. They've been consistent. You know, they've been technocratic in the historical sense that FDA has always been technocratic. And I think that's good. And I hope that continues. I think it was sort of interesting. I…

Graig Suvannavejh

Just one comment on the FDA functioning. This is close. I think it will be close to a record year of drug approvals. It's definitely in the top five, I think, across Cedar and Sieber. So that, I mean, for that metric, that's pretty good for our industry. I agree.

Brian Skorney

I would note something else, which is I'm personally paying a lot of attention to the Trump administration. And so, you know, we saw Stephen Miller come back as Trump's chief of staff. And so in general, I think people view him very negatively. I certainly don't have a positive view on what Trump…

Matt Gline

House cyber director with a woman named Kristen Davies, who frankly looks very qualified for the job. And like, that's an important job right now in the United States. And, you know, the news stories say that Stephen Miller was behind that. And, you know, there's a theory that maybe the second half…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout